Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials

INTRODUCTION: Novel therapies have allowed psoriasis patients to achieve high levels of skin clearance and meaningful improvements in health-related quality of life measures; however, duration of these outcomes has not been evaluated. This study aimed to estimate the duration of Psoriasis Area and S...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebwohl, Mark G., Soliman, Ahmed M., Yang, Hongbo, Wang, Jessie, Hagan, Kaitlin, Padilla, Byron, Pinter, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850479/
https://www.ncbi.nlm.nih.gov/pubmed/34921669
http://dx.doi.org/10.1007/s13555-021-00660-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850479/
https://www.ncbi.nlm.nih.gov/pubmed/34921669
http://dx.doi.org/10.1007/s13555-021-00660-3

Ejemplares similares